Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ·Healthcare·Biotechnology·Mkt cap $409.4M
$14.08
▲ +0.43%
P/E
-4.99
Mkt Cap
$409.4M
52-Wk Range
$7.05–$17.15
52-Week Range
$7.05 - $17.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 58.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary small molecule drug discovery platform with proven track record
- Strategic partnership with Abbott Laboratories providing royalty revenue and validation
- Focused pipeline targeting high-prevalence viral infections with significant market opportunities
- Experienced management team with deep expertise in antiviral drug development
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical advancement of RSV and respiratory virus programs addressing large patient populations
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+27.2% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ENTA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 16, 2026
AUG 10, 2026
Reported EPS of -$0.67 vs -$0.51 consensus (-31.5% surprise). Revenue of $14.4M vs $16.8M expected (-14.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-31.5%
Revenue trend · last 8Q
—
—
-6%
-12%
+2%
+4%
+10%
-22%
Q3 24
Q4 24
Q1 24
Q2 25
Q3 25
Q4 25
Q1 25
Q3 26
$18.0M
$14.6M
$17.0M
$14.9M
$18.3M
$15.1M
$18.6M
$14.4M
Margins · last 8Q
Gross
—
Operating
-120.0%
Profit
-135.8%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ENTA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related